[144] Disc Medicine, Inc. SEC Filing

Rhea-AI Filing Summary

AC Immune SA (ACIU) has filed a Form 144 notice stating that an insider intends to sell up to 20,000 common shares through Morgan Stanley Smith Barney beginning on 24 Jul 2025. The proposed sale, valued at roughly $46,800, stems from stock options exercised on 1 Jun 2012. With 100.41 million shares outstanding, the transaction equals only about 0.02 % of the float. No other insider sales by this filer occurred during the past three months.

Form 144 is a preliminary notice and does not obligate the seller to complete the trade; it simply satisfies SEC Rule 144 requirements for resales of restricted or control securities. Given the modest size, the filing is unlikely to affect liquidity or pricing materially and appears to be a routine portfolio-management move rather than a signal about AC Immune’s operating outlook.

Insights

Securities Analyst

TL;DR: Small insider Form 144 (20k shares, 0.02 % float) – signal neutral, minimal market impact.

The planned disposition totals less than $50k, a de-minimis amount relative to AC Immune’s capitalization. Rule 144 filings are procedural and do not guarantee execution, so liquidity pressure should be negligible. Lack of other recent sales suggests no broader disposal trend. Investors typically view sales of this scale as routine diversification rather than bearish commentary on fundamentals. Accordingly, I classify the news as neutral/not impactful for valuation or sentiment.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch One Bryant Park New York NY 10036	23245	1416550.30	34634295	07/24/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	05/01/2020	Private Placement	Issuer			23245	05/01/2020	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Atlas Venture Fund X, L.P. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	07/18/2025	1184	72375.20
Atlas Venture Opportunity Fund I, LP. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	07/18/2025	664	40588.80
Atlas Venture Fund X, L.P. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	07/23/2025	53215	3244656.91
Atlas Venture Opportunity Fund I, LP. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	07/23/2025	29837	1819239.47

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many AC Immune (ACIU) shares are being registered for sale?

The Form 144 covers 20,000 common shares.

What is the approximate value of the proposed AC Immune share sale?

The aggregate market value is $46,800.

When can the insider begin selling the ACIU shares?

Sales may start on or after 24 July 2025.

How significant is the sale relative to AC Immune’s share count?

It represents roughly 0.02 % of the 100.41 million shares outstanding.

Were there any insider sales by this filer in the prior three months?

No; the form states "Nothing to Report" for that period.